Abstract: The atypical antipsychotic agent clozapine (CLZ) is effective in many patients who are resistant to conventional antipsychotic drugs. Cytochromes P450 (CYPs) 1A2 and 3A4 oxidize CLZ to norCLZ and CLZ N-oxide in human liver. Concurrent treatment with inducers and inhibitors of CYP1A2 modulates CLZ elimination that disrupts therapy. Drug-drug interactions involving CYP3A4 are also significant but less predictable. To further characterize the factors underlying these interactions, we used samples from a cohort of human livers to assess variation in CLZ oxidation pathways in relation to intrinsic CYP3A4 and CYP1A2 activities and the effects of the corresponding selective inhibitors ketoconazole (0.2 and 2 lM) and fluvoxamine (1 and 10 lM). The CYP3A4-selective inhibitor ketoconazole (2 lM) impaired CLZ N-oxide formation in all 14 of the livers used in inhibition studies (≥50% inhibition) while the CYP1A2-selective inhibitor fluvoxamine (10 lM) decreased norCLZ formation in nine. Ketoconazole effectively inhibited CLZ metabolism in five of seven livers that catalysed CYP3A4-dependent testosterone 6b-hydroxylation at or above the median rate and in four other livers with lower intrinsic CYP3A4 activity. Similarly, fluvoxamine (10 lM) readily inhibited CLZ oxidation in seven livers with high CYP1A2-mediated 7-ethoxyresorufin O-deethylation activity (at or above the median) and three livers with lower intrinsic CYP1A2 activity. In three livers, CLZ biotransformation was impaired by both ketoconazole and fluvoxamine, consistent with a major role for both CYPs. These findings suggest that the intrinsic activities of CYPs 1A2 and 3A4 are unrelated to the response to CYP-selective inhibitors and that assessment of the activities in vivo may not assist the prediction of drug-drug interactions.
The atypical antipsychotic drug clozapine (CLZ) is effective in many schizophrenia patients who exhibit treatment resistance to conventional antipsychotic agents. However, in some patients, CLZ also precipitates serious adverse events such as agranulocytosis, cardiotoxicity and seizures [1] . At standard doses, CLZ may produce variable serum concentrations due to individual differences in drug elimination [2, 3] . Decreased elimination may increase serum CLZ concentrations and toxicity while rapid rates of metabolism may lead to subtherapeutic drug concentrations in serum. Thus, it has been suggested that in vivo phenotyping with well-tolerated CYP substrates may be useful in dosage optimization with CLZ and other antipsychotic agents [4] [5] [6] [7] [8] .
Hepatic CLZ biotransformation by cytochrome P450 (CYP)-mediated N-demethylation and N-oxygenation generates the major metabolites norCLZ and CLZ N-oxide, respectively. The principal CYPs that mediate CLZ biotransformation are CYP1A2 and CYP3A4 [9] [10] [11] [12] [13] . Importantly, these CYPs are readily inducible and inhibited by certain co-administered drugs and/or exogenous chemicals. Thus, pharmacokinetic drug-drug interactions (DDIs) that disrupt therapy may occur in patients who receive CLZ and concurrent exposure to CYP inducers and inhibitors.
DDIs associated with CYP1A2 and CYP3A4 induction have been widely reported. Schizophrenia patients who smoke may be difficult to treat with CLZ because the polycyclic aromatic hydrocarbons present in cigarette smoke activate the aryl hydrocarbon receptor that induces hepatic CYP1A2 gene expression [14] and increases CLZ clearance [15, 16] . There have also been clinical reports that activators of the pregnane-X receptor such as rifampicin, carbamazepine, phenytoin and St John's wort that induce CYP3A4 expression accelerate CLZ clearance [17] [18] [19] [20] [21] [22] .
A number of clinical studies have also shown that administration of drugs that inhibit CYP1A2, such as the selective serotinin reuptake inhibitor fluvoxamine, caffeine, the fluoroquinolone antibacterials and the antipsychotic agent perazine, inhibit CLZ clearance and can precipitate CLZ toxicity [2, [23] [24] [25] [26] . In some psychiatric patients who smoke, fluvoxamine coadministration has been found to normalize CLZ clearance and restore therapeutic concentrations in serum [27, 28] . There have been similar reports of DDIs with CYP3A4 inhibitors like erythromycin, fluoxetine and imidazole antifungal agents, which also precipitate toxicity by inhibiting CLZ elimination [29] [30] [31] [32] . However, although significant in some patients, DDIs involving CYP3A4 inhibition occur in a non-uniform fashion [33] [34] [35] [36] . At present, DDIs with CYP3A4 inhibitors are difficult to predict and it is unclear whether in vivo phenotyping could prevent DDIs.
To begin to evaluate the susceptibility of patients to DDIs involving CLZ and the value of in vivo phenotyping, greater information on the extent of the individual variation in inhibitory interactions is required. Accordingly, the present pre-clinical study evaluated the capacity of selective CYP1A2 and CYP3A4 inhibitors to modulate major CLZ biotransformation pathways in a cohort of human liver microsomes. The major finding was that pathways of norCLZ and CLZ N-oxide formation in most livers were susceptible to the CYP1A2 inhibitor fluvoxamine and the CYP3A4 inhibitor ketoconazole, respectively. Importantly, however, susceptibility to inhibition was unrelated to the intrinsic microsomal activity of CYP1A2 or CYP3A4 so that prediction of DDIs in individual patients using in vivo phenotyping is unlikely to be informative.
Materials and Methods
Drugs and chemicals. CLZ and its metabolites, caffeine and its metabolites, 7-ethoxyresorufin, resorufin, dextromethorphan and dextrorphan, fluvoxamine, ketoconazole, and biochemicals were from Sigma-Aldrich (Castle Hill, NSW, Australia) or Roche Pty Ltd (Castle Hill, NSW, Australia). [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] C]-Testosterone (specific activity 59 mCi/ mmol) was from Amersham GE Healthcare (Rydalmere, NSW, Australia), and reagents for electrophoresis were from Bio-Rad (Richmond, CA, USA). HPLC-grade solvents were from RhonePoulenc (Baulkham Hills, NSW, Australia), and analytical reagents were from Ajax (Sydney, NSW, Australia). The preparation and characteristics of the anti-CYP peptide antibodies have been reported elsewhere [37] .
Liver donors and preparation of microsomal fractions. Experiments in human liver were approved by the Western Sydney Area Health Service and University of Sydney ethics committees, according to the Declaration of Helsinki. Liver from 24 donors (HL1-24) was provided through the Australian and Queensland Liver Transplant Programs (Royal Prince Alfred Hospital, Sydney, NSW, and Princess Alexandra Hospital, Brisbane, Queensland, Australia, respectively). Clinical information was available for 12 of the donors. Two were smokers (HL10 and HL14) and one used alcohol (HL19). Regarding drugs that have been reported to interact with CYPs as substrates, inhibitors or inducers, two patients received spironolactone (HL6, HL14) and one each received hydrocortisone (HL24), omeprazole (HL10), prednisone (HL23), propranolol (HL24), ranitidine (HL15) or simvastatin (HL2). EROD and testosterone 6b-hydroxylation activities in microsomal fractions from patients who received the potential inhibitory agents spironolactone and simvastatin were above the median values. In the omeprazole-treated donor (HL10), 7-ethoxyresorufin O-deethylation (EROD) activity was above the median while testosterone 6b-hydroxylation activity was below the median (Table S1) .
Tissue was obtained from the superior surface of the right lobe within 15 min. of removal, perfused with cold Viaspan (DuPont, Wilmington, DE, USA) and then snap-frozen in liquid nitrogen. In the case of some of the donors (HL15-24), the quantity of liver tissue was limited. Hepatic microsomes were prepared by differential ultracentrifugation in potassium phosphate buffer (0.05 M, pH 7.4, containing 1 mM EDTA and 20% glycerol; [38] ) and stored at À70°C. Microsomal protein content was determined as described previously [39] . Because inhibition studies require relatively large amounts of microsomal protein, these studies could only be conducted in 14 livers (HL1-14).
HPLC analysis of CLZ biotransformation. Microsomal CLZ oxidation to norCLZ and CLZ N-oxide was determined as described by Zhang et al. [13] . Incubations contained 0.2 mg microsomal protein and 100 lM CLZ (or 10 lM in inhibition studies) in 0.1 M potassium phosphate buffer (pH 7.4; final volume 0.25 mL; 37°C) and were initiated with NADPH (1 mM). After 15 min., reactions were terminated with 1 mL of cold 0.1% formic acid. Metabolite formation was linear under these conditions. Inhibition of CLZ oxidation by fluvoxamine (1 and 10 lM) and ketoconazole (0.2 and 2 lM) was determined in duplicate in individual microsomal fractions (HL1-14). CLZ metabolites formed in incubations were subjected to solid-phase extraction (Oasis HLB; Waters Corp, Milford, MA, USA) and separated on a Synergy Fusion-RP polar embedded C 18 column (250 9 4.6 mm, 4 m; Phenomenex Australia Pty Ltd, Pennant Hills, NSW; 38°C using a flow rate of 1.0 mL/min; 260 nm detection). The mobile phase was acetonitrile:methanol:20 mM ammonium acetate buffer (3:2:5, pH 5.0), containing N,N-dimethyloctylamine (0.4 mL/L). Retention times of authentic norCLZ, doxepin (internal standard) and CLZ N-oxide were 11.4, 13.1 and 16.9 min., respectively.
HPLC analysis of caffeine biotransformation. Microsomal caffeine biotransformation was conducted essentially as described by Tassaneeyakul et al. [40] . Incubations contained 0.5 mg microsomal protein and 10 mM caffeine in 0.1 M potassium phosphate buffer (pH 7.4; final volume 0.25 mL; 37°C) and were initiated with NADPH (1 mM). After 15 min., reactions were terminated with 5 mL of cold chloroform:isopropanol (80:20). Caffeine and its metabolites were separated on a Synergy Fusion-RP polar embedded C 18 column (250 9 4.6 mm, 4 m; Phenomenex Australia Pty Ltd) using a flow rate of 1.0 mL/min (273 nm detection). The mobile phase was sodium acetate buffer (25 mM, pH 4.0):methanol (86:14). Retention times of authentic theobromine, paraxanthine, theophylline, 1,3,7-trimethyluric acid, b-hydroxyethyltheophylline (internal standard) and caffeine were 11.0, 15.5, 16.8, 18.4, 18.9 and 29.6 min., respectively.
Other assays of CYP function in human hepatic microsomes. EROD activity (0.05 mg protein/0.2 mL incubation; 7-ethoxyresorufin 2.5 lM) was estimated spectrofluorometrically in Tris-HCl buffer (0.1 M, pH 7.8) using the excitation/emission wavelength pair of 560/ 580 nm [41] . Testosterone 6b-hydroxylation (0.15 mg protein/0.4 mL incubation;
14 C-testosterone 50 lM, 0.18 lCi) was estimated in potassium phosphate buffer (0.1 M, pH 7.4) as described previously [42] . After 2.5 min., products were extracted with chloroform, separated by thin-layer chromatography and quantified by scintillation spectrometry. Dextromethorphan O-demethylation (0.15 mg protein/ 0.25 mL incubation; dextromethorphan 16 lM) was measured in potassium phosphate buffer (0.1 M, pH 7.4) as described by Vielnascher et al. [43] . After 30 min., products were isolated on solidphase cartridges (Oasis HLB), washed with 10% aqueous methanol and then eluted with methanol. Quantification was by LC-mass spectrometry on a Finnigan MAT TSQ 7000 LC-MS/MS system (San Jose, CA, USA) using electrospray ionization (positive ion mode) and a mobile phase of 50% aqueous acetonitrile, containing 0.1% formic acid.
Immunoquantification of microsomal proteins. Human liver microsomes (15 lg of protein per lane) were electrophoresed on 7.5% polyacrylamide gels containing 5% 2-mercaptoethanol and 2% sodium dodecyl sulphate [44] . Proteins were transferred to Protran nitrocellulose (Schleicher and Schuell, Dassel, Germany) and were subjected to Western immunoblotting. Monospecific rabbit antibodies directed against peptides that corresponded to the C-terminal regions of human CYP1A2, CYP2D6 and CYP3A4 were prepared as described previously [37] . Immunoreactive proteins were detected by enhanced chemiluminescence and autoradiography on Hyperfilm MP (Amersham) and quantified by densitometry (Bio-Rad, Richmond, CA, USA).
Statistics. Data are presented as medians and ranges of measurements in hepatic fractions from individuals (n was either 14 or 24, as indicated). Spearman's correlation coefficients were obtained using StatView (Abacus concepts, Berkeley, CA, USA).
Results
Individual variation in the oxidation of CLZ and other substrates in human liver microsomes. The major oxidized metabolites of CLZ ( fig. 1A) were estimated in twenty-four individual human liver microsomal fractions (HL1-24; fig. 2A , Table S1 ). NorCLZ formation varied over a~6-fold range (2.4-14.5 nmol/mg protein/h; median 5.3) whereas CLZ N-oxide formation varied over a~20-fold range (0.9-18.4 nmol/mg protein/h; median 4.3; fig. 2A ; Table S1 ). In comparison, the 6b-hydroxylation of the CYP3A4 substrate testosterone varied over a~17-fold range in the microsomal fractions (21-365 nmol/mg protein/h; median 127; HL1-24; fig. 2A , Table S1 ) and EROD activity mediated by CYP1A2 varied over a~15-fold range (0.2-2.9 nmol/ mg protein/h; median 1.1; fig. 2A ; HL1-24, Table S1 ). To support these observations, we also assessed the biotransformation of caffeine in a number of livers (HLs 1, 6, 9-11, 13-21) because the formation of its metabolites is also mediated by CYPs 1A2 and 3A4 (fig. 1B) . The CYP1A2-dependent N3-demethylation of caffeine to paraxanthine, N1-demethylation to theobromine and N7-demethylation to theophylline all varied over a~2-4-fold range. In contrast, the CYP3A4-mediated 8-hydroxylation of caffeine to 1,3,7-trimethyluric acid varied over a~5-fold range (4.0-19.9 nmol/mg protein/h; median 8.3; fig. 2A ; Table S1 ). Within the subset of donor livers that was available for the measurement of caffeine metabolism, norCLZ and CLZ N-oxide formation, EROD and testosterone 6b-hydroxylation activity varied over 5.6-, 20-, 9.1-and 15-fold ranges, respectively. In comparison, the activity of the CYP2D6-mediated O-demethylation of dextromethorphan was also quite variable (0.1-23 nmol/mg protein/h; median 7.8; fig. 2A ; Table S1 ).
Relationship of CLZ biotransformation to other CYP-mediated substrate oxidations in human liver microsomes. Regression analysis was used to correlate the formation of CLZ metabolites with well-defined substrate oxidations mediated by CYPs 1A2, 3A4 and 2D6. norCLZ formation was correlated with CYP3A4-mediated testosterone 6b-hydroxylation (q = 0.62, p < 0.01) and CYP1A2-catalysed EROD activity (q = 0.57, p < 0.01; table 1). CLZ N-oxide formation was correlated with testosterone 6b-hydroxylation (q = 0.52, p < 0.05) but not EROD activity (q = 0.24; table 1). norCLZ formation was also correlated with the oxidation of caffeine to paraxanthine and theobromine (q = 0.58-0.59, p < 0.05; table 1). As expected, CYP1A2-catalysed EROD activity and formation of paraxanthine, theobromine and theophylline were well correlated (q = 0.70-0.75, p < 0.05 or p < 0.01), while CLZ N-oxide formation was correlated with 1,3,7-trimethyluric acid formation (q = 0.56, p < 0.05); testosterone 6b-hydroxylation and 1,3,7-trimethyluric acid formation were also correlated (q = 0.70, p < 0.05). The dominant roles of either CYP1A2 or CYP3A4, which mediate EROD and testosterone 6b-hydroxylation activities, respectively, in the formation of caffeine metabolites may underlie the larger correlation coefficients than those with the formation of CLZ metabolites that involve contributions from both enzymes [10] [11] [12] [13] .
The expression of CYPs 1A2, 3A4 and 2D6 was also assessed in human liver microsomal fractions using monospecific anti-CYP peptide antibodies ( fig. 2B ). Interindividual variation in expression was considerable for the polymorphically distributed CYP2D6 (range 0-1.6-fold) and the highly inducible CYPs 1A2 and 3A4 (ranges 0-2.8-and 0.5-4.1-fold, respectively). Spectrophotometric CYP determination requires relatively large amounts of microsomal protein. In this 
Differential inhibition of CLZ metabolite formation in individual human livers.
The major focus of this study was to assess the variation in the roles of CYP1A2 and CYP3A4 in CLZ oxidation in 14 individual donor livers using the selective inhibitors fluvoxamine (1 and 10 lM) and ketoconazole (0.2 and 2 lM) [9] [10] [11] [12] [13] . Studies were undertaken at a CLZ concentration of 10 lM because this reflects concentrations of the drug in serum and liver during treatment [45] . There was considerable variation in the extent of inhibition of norCLZ formation by the CYP3A4-selective inhibitor ketoconazole (range 10-85%; median 29%, at a 2 lM concentration; fig. 3A ), whereas the inhibition of CLZ N-oxide formation was extensive in all livers (range 50-88%; median 71%, at a concentration of 2 lM (fig. 3B ). On the other hand, norCLZ formation was susceptible to the CYP1A2-selective inhibitor fluvoxamine (range 18-100%; median 53%, at a 10 lM concentration; fig. 3C ) while CLZ N-oxide formation was refractory in most livers (range 25-88%; median 31% at a concentration of 10 lM (fig. 3D ). As anticipated, lower concentrations of the inhibitors (fluvoxamine 1 lM and ketoconazole 0.1 lM) generally effected less inhibition of CLZ biotransformation. In some livers, however, inhibition at the lower concentrations was more pronounced. The reason for this is unclear although it is noteworthy that the reported K m values for microsomal CLZ metabolite formation are in the range 100-300 lM [11, 13] , which is well in excess of the clinically relevant concentration (10 lM) used in this study. In summary, using the criterion of ≥50% inhibition at the higher concentration of ketoconazole (2 lM), there was effective inhibition of CLZ N-oxide formation in all 14 of the microsomal fractions, while fluvoxamine at the higher concentration (10 lM) was an effective inhibitor of norCLZ formation in eight of the livers (HL1, 2, 4-6, 8, 10 and 13; fig. 3E ). In contrast, ketoconazole (2 lM) only produced marked inhibition of norCLZ formation in two livers (HL5 and HL8) while fluvoxamine (10 lM) effectively inhibited CLZ N-oxide formation in only three (HL2, HL5 and HL14; fig. 3E ).
We assessed the potential relationships between the activities of CYPs 3A4 and 1A2 in human liver microsomes, as reflected by testosterone 6b-hydroxylation and EROD, respectively, and the inhibition of CLZ biotransformation produced by fluvoxamine and ketoconazole. Livers were classified on the basis of whether CYP1A2 and CYP3A4 activities were above or below median values, and the susceptibility of norCLZ and CLZ N-oxide formation in each liver to inhibition by the upper concentrations of ketoconazole (2 lM) and fluvoxamine (10 lM) was assessed. Five of the livers in which CLZ biotransformation was inhibited most extensively (median and over) by ketoconazole (2 lM) also exhibited high testosterone 6b-hydroxylation activity (HL1, 3, 6, 7 and 9; fig. 3F , Table S1 ). Importantly, however, CLZ oxidation in four other livers was readily inhibited by ketoconazole even though their intrinsic CYP3A4 activity was relatively low (below the median) (HL5, 8, 11 and 12; fig. 3F , Table S1 ). Conversely, seven of the livers in which CLZ oxidation was readily inhibited by the upper concentration of fluvoxamine (10 lM) also exhibited relatively high EROD activity (≥me-dian; HL2, 4, 6, 7, 10, 13 and 14; fig. 3F , Table S1 ), but three livers in which EROD activity was relatively low were highly responsive to fluvoxamine (10 lM; HL3, 5 and 8; fig. 3F , Table S1 ). In three livers -HL6-8 -there was significant inhibition of one or both pathways of CLZ oxidation by ketoconazole (2 lM) and fluvoxamine (10 lM), which suggests that both CYP1A2 and CYP3A4 had important roles in CLZ biotransformation in those livers.
Discussion
Previous studies have implicated human hepatic CYPs 1A2 and 3A4 in the oxidative biotransformation of CLZ [9] [10] [11] [12] [13] . Moreover, in vivo phenotyping with small doses of well-tolerated CYP substrates has corroborated the clinical relevance of these enzymes in CLZ elimination [4, 5, 7, 8, 24] . Such approaches may assist clinicians in determining the optimal dosage of CLZ in individual patients. However, it is unclear whether such approaches may be useful in identifying patients who may be at risk from DDIs due to co-administered drugs that inhibit CYP1A2 or CYP3A4. In this study, we assessed the relationships between intrinsic CYP1A2 and CYP3A4 activities in human liver and the susceptibility of CLZ oxidation pathways to selective inhibitors of the enzymes. The principal finding to emerge was that, at concentrations near the therapeutic range during treatment with CLZ (~10 lM), the activities of the major CLZ-oxidizing CYPs were independent from the responses to CYP-selective inhibitors. The potential significance is that in vivo phenotyping with CYP1A2/ CYP3A4 substrates may have limited value in predicting patients who may be susceptible to DDIs with co-administered drugs.
In vivo studies in patients have established that CYP1A2 has a major role in CLZ elimination. Exposure to CYP1A2 inducers, such as cigarette smoke chemicals, has been shown to increase CLZ clearance and to compromise therapy with the drug [15, 16, 27, 28] . Inhibitory DDIs with CYP1A2 substrates and inhibitors like fluvoxamine, caffeine and fluoroquinolone antibacterials also appear to be quite predictable [22, 23, 25, 26] . In contrast, the significance of CYP3A4 in CLZ clearance has been somewhat more contentious. DDIs attributable to CYP3A4 induction and inhibition have been reported but in relatively few patients [2, [17] [18] [19] [20] [21] [22] [29] [30] [31] [32] . Thus, the macrolide antibiotic erythromycin increased serum CLZ concentrations and precipitated adverse events in several schizophrenia patients that resolved after erythromycin discontinuation [29, 31] . Other drugs, such as fluoxetine and the antimycotic imidazoles miconazole and fluconazole, that also inhibit CYP3A4 rather than CYP1A2, may precipitate toxicity in some patients who received CLZ [30, 32] . The consequences, although significant, have usually been reported in small numbers of patients. Thus, there is a need to understand in greater detail the roles of CYPs 1A2 and 3A4 in CLZ clearance to appreciate why relatively few patients experience DDIs during therapy with CLZ and CYP3A4 inhibitors.
The CYP selectivity of the inhibitors fluvoxamine and ketoconazole is an important consideration. In early studies, fluvoxamine was found to be a potent inhibitor of CYP1A2-mediated EROD activity in human liver microsomes (IC 50 0.3 lM) but was 200-fold less potent as an inhibitor of CYP3A4-mediated testosterone 6b-hydroxylation (IC 50 60 lM; [46] ). Conversely, ketoconazole was a potent inhibitor of testosterone 6b-hydroxylation (IC 50 0.22 lM [47] ) and was only a moderate inhibitor of CYP1A2 activity (IC 50 ≥60 lM [46] ). From studies with recombinant enzymes, it was suggested that fluvoxamine may generate a metabolite intermediate complex with CYP3A4 [48] . However, the reported efficiency of complex formation between fluvoxamine and CYP3A4 (k inact /K I ) was only around 1% of that of well-established agents like troleandomycin [48] . Moreover, a subsequent report was unable to confirm time-dependent inhibition of human hepatic CYP3A4 by fluvoxamine [49] . Together, these findings suggest that this mechanism may be only a minor component of any inhibition of CYP3A4 by fluvoxamine.
There have also been in vivo studies that have assessed the selectivity of CYP inhibition by fluvoxamine. While in vivo inhibition of CYP1A2 and CYP2C19 by fluvoxamine is well established [50] , there is conflicting information regarding CYP3A4 inhibition. Thus, in human individuals, fluvoxamine minimally altered the clearance of carbamazepine, quinine and omeprazole, whose metabolism is at least partially dependent on CYP3A4 [51] [52] [53] . In contrast, fluvoxamine was suggested to inhibit alprazolam clearance, although formation of the CYP3A4-dependent 4-hydroxy metabolite was unimpaired [54] . Similarly, fluvoxamine was reported to inhibit the plasma clearance of midazolam in volunteers, although whether this involved a decrease in CYP3A4-dependent midazolam 1 0 -hydroxylation is not clear [55] . Thus, it is feasible that fluvoxamine may impair CYP3A4-independent pathways of alprazolam and midazolam clearance. However, it is now clear that CYP3A4 possesses multiple substrate binding domains within its active region [56] that may give rise to differential effects of inhibitors on particular CYP3A4 substrates [57] . Ketoconazole and fluvoxamine are highly selective inhibitors of CLZ oxidation by recombinant CYP3A4 and CYP1A2, respectively [13] . Thus, ketoconazole (0.2 and 2 lM) decreased norCLZ and CLZ N-oxide formation by CYP3A4, but not CYP1A2, while fluvoxamine (1 and 10 lM) inhibited the CYP1A2-mediated formation of the metabolites. Fluvoxamine had no effect on CYP3A4-mediated norCLZ although it produced a small decrease in CLZ N-oxide formation by that enzyme (to~70-80% of control; [13] ). These agents have also been used as CYP-selective inhibitors of CLZ oxidation in human liver microsomes [11, 13] .
The present findings that CYP1A2 was important in norCLZ formation in most livers while CYP3A4 had the dominant role in CLZ N-oxide formation are consistent with several earlier reports [9] [10] [11] [12] [13] . To date, most clinical studies have quantified CLZ and, in some cases, norCLZ in serum of schizophrenia patients; with the exception of a recent report, CLZ N-oxide has been quantified in relatively few studies [8] . It may now be appropriate to extend routine therapeutic drug monitoring [58] , which is used during the early phase of CLZ therapy, to quantify CLZ and both of its major metabolites in serum. This may have value in identifying CLZ clearance pathways that are important in individual patients.
The factors that predispose some patients to adverse effects from concurrent CYP3A4 inhibitors remain unclear. A potentially interesting possibility is suggested by the study of Jaquenoud et al. [59] . In that report, serum concentrations of CLZ did not correlate well with CYP3A4 activity across the full patient cohort, although a relationship was evident in patients who also received fluvoxamine. In this situation, it is likely that CYP1A2 was functionally impaired, which could unmask a more significant contribution of CYP3A4 in CLZ clearance, and which may then increase the likelihood of DDIs with CYP3A4 inhibitor drugs. Indeed, it is noteworthy that CYP1A2 activity is known to be strongly decreased in patients with infections [60] . In accord with this finding, CLZ biotransformation and clearance are also impaired in patients with infections [61] and possibly other pathophysiological states in which inflammatory activity is increased, such as liver injury [62] , which potentially could precipitate toxicity with the drug. Moreover, in case reports of DDIs with CYP3A4 inhibitors like erythromycin and antifungal imidazoles, these drugs were administered to patients with concurrent infections [29, 31, 32] . It is feasible that CYP1A2 function may have been impaired in these patients because of infection, leaving a more important role for the alternate enzyme CYP3A4 in CLZ elimination. It would now be of interest to assess this possibility directly in patients.
